CancerIQ’s Post

This July we honor the legacy of Peyton Rous, the Nobel Prize laureate who discovered tumor-inducing viruses. His groundbreaking work laid the foundation for modern tumor virology and opened new avenues in cancer research. Rous's discovery of the Rous sarcoma virus (RSV) from a chicken sarcoma transformed our understanding of viral oncology and sarcoma biology. Peyton Rous's pioneering work in isolating a filterable agent from a sarcoma in the breast muscle of a hen, now known as RSV, was a monumental step in cancer research. This discovery demonstrated that viruses could induce tumors, fundamentally altering our approach to understanding cancer causation and progression. Rous's work was instrumental in the identification of oncogenes and the role of viruses in cancer, bridging the gap between biological and molecular eras. Rous's contributions highlight the critical importance of data-driven translational research in the fight against sarcoma. By utilizing advanced technologies like single-cell RNA sequencing and protein-protein interaction network analysis, researchers can uncover the complex interactions between viral and host proteins. Understanding these interactions is essential for identifying new therapeutic targets and developing effective treatments for sarcoma patients. For instance, investigating the protein-protein interaction networks between RSV proteins and host cell proteins can reveal potential mechanisms of oncogenesis and identify novel drug targets. Such studies not only enhance our understanding of sarcoma biology but also pave the way for innovative therapeutic strategies that can improve patient outcomes. With our AI Platform for translational research, we are committed to building on the legacy of researchers like Peyton Rous. Our platform leverages AI to analyze complex datasets, identify key molecular interactions, and accelerate the discovery of new therapies. By integrating patient-led research with advanced computational tools, we aim to uncover new insights into sarcoma and other cancers. This Sarcoma Awareness Month, let's celebrate the contributions of Peyton Rous and the ongoing advancements in sarcoma research. Together, we can drive forward the development of innovative treatments and improve the lives of patients affected by challenging diseases. #SarcomaAwarenessMonth #PeytonRous #TumorVirology #CancerResearch #TranslationalResearch #AIinHealthcare #SarcomaResearch #DrugDiscovery #SupportSarcomaPatients #HealthcareInnovation

Cancer cells are driven by the same imperative guiding all living things: to grow, survive and reproduce. Although cancer’s evolutionary underpinnings have been recognized since the 1950s, clinicians have been slow to apply the lessons of evolution to the fight against this deadly disease, which remains the second-leading cause of death, claiming 9.7 million lives worldwide in 2022. A new review by Arizona State University researcher Carlo Maley and Lucie Laplane from the Université Paris 1 Panthéon-Sorbonne examines the prevailing theory of cancer evolution. The authors highlight both practical and theoretical limitations of the clonal model of cancer evolution and propose areas for improving the model’s relevance and accuracy. The study suggests that the model could be improved by acknowledging that cancer cells inherit not only genetic mutations but also other traits that allow them to rapidly adapt to their environment — even without genetic alterations. Cancer cells are highly responsive to their surrounding environment, which can promote or suppress their growth. Further, cancer evolution often follows complex dynamics, leading to tangled and unpredictable growth patterns. Cancer biologists have traditionally defined a "clone" as a group of cells descending from a single ancestor cell and sharing the same genetic makeup. But cancer cells mutate so fast that no two cells have the same genetic makeup. The study proposes replacing the concept of a clone with a focus on the cell genealogies that record the history and define the structure of the cells in a tumor. The value of an effective model lies in its ability to explain how and why cancers evolve and respond to therapy. By refining the clonal evolution model, the study paves the way for more effective cancer therapies that consider the full complexity of cancer cell evolution. The research appears in the current issue of the journal Nature Reviews Cancer. Read the full story on ASU news: https://ow.ly/LAuy50TlkZH Discover the latest in cancer research, from diagnosis and treatment to prevention, as the ASU Biodesign Institute takes a comprehensive approach. Learn more: https://ow.ly/RylC50Tllp1 #ASUResearch #Innovation #Evolution #CancerResearch #Bioscience #ASU #Health #Research

𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗻𝗴 #𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗶𝘀𝗸𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗮𝘀𝗶𝘀 𝗼𝗳 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 #𝗱𝗮𝘁𝗮: Scientists from the German cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems. It could help to identify people with a high risk of cancer, for whom individualized early detection programs could be tested in studies. If cancers are detected early, the chances of cure are generally higher and patients require less intensive treatment. However, screening programs for the early detection of cancer only exist for a few tumor diseases - and not all people take advantage of these offers. 𝗜𝗳 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗿𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗲𝗱 𝗲𝗮𝗿𝗹𝘆, 𝘁𝗵𝗲 𝗰𝗵𝗮𝗻𝗰𝗲𝘀 𝗼𝗳 𝗰𝘂𝗿𝗲 𝗮𝗿𝗲 𝗴𝗲𝗻𝗲𝗿𝗮𝗹𝗹𝘆 𝗵𝗶𝗴𝗵𝗲𝗿: https://lnkd.in/erGYstF4 DKFZ Deutsches Krebsforschungszentrum, European Bioinformatics Institute | EMBL-EBI, Alex Jung, Peter Christoffer Holm, Kumar Gaurav, Jessica Hjaltelin, Davide Placido, Laust Mortensen, Ewan Birney, Søren Brunak, Moritz Gerstung

Researchers can now access a large bank of paediatric genomic data collected as part of the Children's Cancer Institute ZERO Childhood Cancer program in the newly released data portal 🔗 https://lnkd.in/gi9A9vWd Read more about our collaboration with CCI and the ZERO program, which formed part of the Human Genomes Platform Project 👇 https://lnkd.in/gVgcHsyH The data portal is backed by the Global Alliance for Genomics and Health's Beacon network, which the HGPP team adapted for use in Australia #genomics #cancer #collaboration #data

Another step toward incorporating Whole Genome Sequencing into routine cancer care! According to a recent study conducted at Great Ormond Street Hospital and Cambridge University Hospitals Trust, studying the entire genetic sequence of a child's cancer provides critical insights, improving care in many cases. The Recent research involving 281 children showed that nearly a third benefited from additional information about their illness and treatment. Whole genome sequencing offers reassurance, guides treatment, and aids in future research. The lead author of the study, Dr Jack Bartram at Great Ormond Street Hospital stated: "In-depth genetic understanding of cancer is crucial in guiding our practice" And I couldn't agree more! There's much talk on the promise of precession medicine but this recent study highlights that we need to incorporate Whole Genome Sequencing in routine cancer care. #CancerResearch #Genomics #NHS #ChildHealth #MedicalInnovation

“The observational study, which began enrollment late last year, will include 1,500-2,000 Black men and women diagnosed with prostate or breast cancers, respectively, from the U.S., the nine-nation African Caribbean Cancer Consortium, and a broad swath of the African subcontinent. The goal is to build a specific cancer registry for these two prevalent cancers in populations of African descent. The study will attempt to identify not only novel genetic and molecular drivers of these cancers, but also their social determinants, such as health care access and lifestyle factors that influence the mutational landscape, to build a comprehensive database.” #precisionmedicine #clinicaltrials #cancer #prostatecancer #breastcancer #healthcaredisparities #genetictesting #genetics #genomics #ngs #oncology #precisiononcology

Landmark Research by ICR Scientists Revolutionizes Understanding of Cancer Development In groundbreaking studies, the Institute of Cancer Research (ICR) has unveiled findings that promise to redefine our approach to cancer treatment. Spearheaded by Professor Trevor Graham, Director of the Centre for Evolution and Cancer, and Professor Andrea Sottoriva, Team Leader of the Evolutionary Genomics and Modelling team, these studies shine a spotlight on the crucial role of epigenetics in the development and progression of bowel cancer. For years, the significance of epigenetics in cancer has been acknowledged, but its specific mechanisms remained elusive. The ICR team's research now provides profound insights into how epigenetic control influences bowel cancers, beyond the effects of DNA mutations. The first study meticulously analyzed 1,373 samples from 30 bowel cancers, establishing that epigenetic changes are prevalent in cancer cells, inheritable, and confer advantages for survival, while also impacting the accumulation of DNA mutations. In a complementary study, the researchers discovered that less than 2% of DNA sequence changes across different tumour sections correlate with gene activity modifications. This indicates that although DNA mutations are foundational in cancer's onset, epigenetic factors largely dictate the behavior of cancer cells. Currently, healthcare professionals rely on testing for DNA mutations to inform cancer treatment, which overlooks the critical epigenetic changes. This gap in diagnostics suggests a need for a more comprehensive testing approach that includes both genetic and epigenetic alterations for optimizing treatment plans and improving patient outcomes. These findings not only broaden our understanding of cancer but also herald a new era in personalized cancer therapy, emphasizing the necessity of integrating epigenetic testing into standard care protocols. #CancerResearch #Epigenetics #BowelCancer #PersonalizedMedicine #InnovationInHealthcare Image: DNA unwinding from histones. The 3D structure of DNA can influence which genes can be turned on and off. Credit: Phospho Biomedical Animation 

This carousel offers an insightful look into the latest advancements in cancer research. From understanding the complexities of our DNA to the potential of new treatment avenues like epigenetics and immunotherapy. Check it out to stay informed on how science is paving the way to ending cancer. 🚀🔬 #EndCancer #MedicalInnovation

"Investigators at the Johns Hopkins Kimmel Cancer Center have developed a machine learning strategy that has shown the potential to predict cases of early-stage lung or liver cancers in humans, by detecting repetitive genetic sequences in the genome in cancerous tissue, as well as in cell-free DNA (cfDNA)." #machinelearning #genomics #cancerresearch #DNAseq #drugdiscovery https://lnkd.in/eckMXKS2

📣 NEWS: “A huge step forward”. ICR researchers, together with a global consortium of scientists, have uncovered genetic clues to the high rates of prostate cancer in Black men. The findings were published in Nature Genetics.   Black men are twice as likely to develop prostate cancer than White European men. This research identified 187 new genetic variants linked to men’s risk of developing prostate cancer, including several that were only found in men with African ancestry. This discovery means that predicting risk of prostate cancer in Black men will be more accurate. Read more about the study this #MensHealthAwarenessMonth 👇 https://lnkd.in/eG6hRxc4